BNP-7787 (BioNumerik/Baxter Oncology/Grelan).
BioNumerik Pharmacology Inc, Baxter Oncology GmbH (formerly ASTA Medica AG) and Grelan Pharmaceutical Co Ltd are developing BNP-7787 for the potential reduction of toxicity associated with cisplatin and carboplatin treatment in cancer patients.
Reilly
R Todd
RT
The Johns Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street Room 4M08, Baltimore, MD 21231, USA. reilly@jhmi.edu
D000818:Animals; D000932:Antiemetics / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D015080:Mesna / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D013329:Structure-Activity Relationship; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy* / Q000517:prevention & control
D000932:Antiemetics; D000970:Antineoplastic Agents; C027032:2,2'-dithiodiethanesulfonic acid; D015080:Mesna